Lv5
1550 积分 2022-06-14 加入
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
2个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
3个月前
已完结
Molecular heterogeneity in prostate cancer and the role of targeted therapy
3个月前
已完结
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
4个月前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
5个月前
已完结
p53 at the crossroads of tumor immunity
8个月前
已完结
MDM2 inhibitors in sarcomas: results and next steps
10个月前
已完结
Clear cell mesotheliomas with inactivating VHL mutations and near‐haploid genomic features
11个月前
已完结
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
11个月前
已完结
皖公网安备34019202002308
